Sulfonamides and sulfonylated derivatives as anticancer agents

Current Cancer Drug Targets

Volumn 2, Issue 1, 2002, Pages 55-75

  Casini, Angela ^a   Scozzafava, Andrea ^a   Mastrolorenzo, Antonio ^a   Supuran, Claudiu T ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

1 (3,4 DICHLOROPHENYL) 3 (2,3 DIHYDROBENZOFURAN 5 YLSULFONYL)UREA; 5 CHLOROSULFAQUINOXALINE; ACETAZOLAMIDE; AMPRENAVIR; ANTINEOPLASTIC AGENT; BETA TUBULIN; CARBONATE DEHYDRATASE; COUMARIN DERIVATIVE; ER 34410; ESTRONE 3 SULFAMATE; ESTRONE SULFATE; FUROSEMIDE; HETEROCYCLIC COMPOUND; INDISULAM; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE INHIBITOR; N [2 [(4 HYDROXYPHENYL)AMINO] 3 PYRIDINYL] 4 METHOXYBENZENESULFONAMIDE; NEUTROPHIL COLLAGENASE; NUCLEAR FACTOR Y; SULFATHIAZOLE; SULFONAMIDE; SULFONYLUREA DERIVATIVE; SULOFENUR; TAMOXIFEN DERIVATIVE; TORASEMIDE; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANIMAL CELL; ANTIBACTERIAL ACTIVITY; ANTINEOPLASTIC ACTIVITY; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CELL CYCLE G1 PHASE; CLINICAL TRIAL; COMPUTER AIDED DESIGN; DIURESIS; DRUG CLASSIFICATION; DRUG DESIGN; DRUG EFFICACY; DRUG MECHANISM; DRUG STRUCTURE; ENZYME INHIBITION; GROWTH INHIBITION; HUMAN; HUMAN CELL; HYPOGLYCEMIA; MICROTUBULE ASSEMBLY; MICROTUBULE ORGANIZING CENTER; NONHUMAN; REVIEW; STRUCTURE ANALYSIS; THYROID FUNCTION; TRANSCRIPTION REGULATION; TUMOR GROWTH;

ANIMALS; ANTINEOPLASTIC AGENTS; CARBONIC ANHYDRASE INHIBITORS; CARBONIC ANHYDRASES; HUMANS; ISOENZYMES; NEOPLASMS; SULFANILAMIDES; SULFATASES; SULFONAMIDES;

EID: 0036279815     PISSN: 15680096     EISSN: None     Source Type: Journal    
DOI: 10.2174/1568009023334060     Document Type: Review

References (84)

1. Novel anticancer drug discovery
2. Clinical multidrug resistance in cancer: A multifactorial problem
3. Blockage of drug resistance in vitro by disulfiram, a drug used to treat alcoholism
4. Genomics and the discovery of new drug targets
5. Drug discovery: A historical perspective
6. Novel sulphonamide derivatives for the treatment of cancer
7. Carbonic anhydrase inhibitors and their therapeutic potential
8. Carbonic anhydrase inhibitors
9. Relations between structure and biological activity of sulfonamides
10. Sulfonylurea receptors, ion channels and fruit flies
11. Isosterism and molecular modification in drug design
12. Bacterial proteases: Current therapeutic use and future prospects for the development of new antibiotics
13. Carbonic anhydrase and matrix metalloproteinase inhibitors. Sulfonylated amino acid hydroxamates with MMP inhibitory properties act as efficient inhibitors of carbonic anhydrase isozymes I, II and IV, and N-Hydroxysulfonamides inhibit both these zinc enzymes
14. Isosterism among analogues of torasemide: Conformational, electronic and lipophilic properties
15. The roles of carbonic anhydrase in metabolism, cell growth and cancer
16. Transcriptional regulation of the MN/CA 9 gene coding for the tumor-associated carbonic anhydrase IX
17. Cloning and characterization of MN, a human tumor-associated protein with a domain homologous to carbonic anhydrase and a putative helix-loop-helix DNA binding segment
18. Carbonic anhydrase IX pastorek MN/CA IX: Analysis of stomach complementary DNA sequence and expression in human and rat alimentary tracts
19. Sly cDNA cloning, expression, and chromosomal localization of a carbonic anhydrase gene that is overexpressed in some renal cell cancers
20. Identification of carbonic anhydrase XII as the membrane isozyme expressed in the normal human endometrial epithelium
21. Isolation characterization of C.A.X.I.V. A novel membrane-bound carbonic anhydrase from mouse kidney
22. Down-regulation of transmembrane carbonic anhydrase in renal cell carcinoma cell lines by wild-type von hippel-lindau transgenes
23. The role of carbonic anhydrase in tumours
24. Renal carbonic anhydrase activity in DBA/2FG-Pcy/Pcy mice with inherited polycystic kidney disease
25. Carbonic anhydrase in human pancreas: Hypotheses for the pathophysiological roles of CA isozymes
26. A carbonic anhydrase inhibitor as a potential modulator of cancer therapies
27. Sulphonamide inhibitors of carbonic anhydrase inhibit the growth of human lymphoma cells in culture
28. Carbonic anhydrase inhibitor suppresses invasion of renal cancer cells in vitro
29. Carbonic anhydrase inhibitors - Part 94. 1,3,4-Thiadiazole-2-sulfonamide derivatives as antitumor agents?
30. Carbonic anhydrase inhibitors: Aromatic sulfonamides and disulfonamides act as efficient tumor growth inhibitors
31. Carbonic anhydrase inhibitors: Synthesis of n-morpholyl-thiocarbonylsulfenylamino aromatic/heterocyclic sulfonamides and their interaction with isozymes I, II and IV
32. Carbonic anhydrase inhibitors: Sulfonamides as antitumor agents?
33. Cellular pharmacology of chloroquinoxaline sulfonamide and a related compound in murine B16 melanoma cells
34. Choloroquinoxaline sulfonamide: A sulfanilamide antitumor agent entering clinical trials
35. Clinical and pharmacology study of chloroquinoxaline sulfonamide given on a weekly schedule
36. Phase II trial of chloroquinoxaline sulfonamide (CQS) in patients with stage III and IV non-small-cell lung cancer
37. Novel sulfonamides as potential systemically active antitumor agents
38. Mechanism of action of E7010, an orally active sulfonamide antitumor agent: Inhibition of mitosis by binding to the colchicine site of tubulin
39. In vivo tumor growth inhibition produced by a novel sulfonamide, E7010, against rodent and human tumors
40. Phase I study of E7010
41. Novel sulfonate derivatives: Potent antimitotic agents
42. ER-34410, a structurally novel sulfonamide as a potential and injectable antitumor agent
43. A focused compound library of novel N- (7-indolyl)benzenesulfonamides for the discovery of potent cell cycle inhibitors
44. Discovery of novel antitumor sulfonamides targeting G1 phase of the cell cycle
45. Antitumor effect of E7070 (ER-35744) against orthotopically transplanted mouse and human colorectal tumors
46. Pharmacokinetic study of E7070 in patients with solid tumors as single I.V. Infusion, weekly x 4, Q 6 weeks
47. Walle pharmacokinetic (PK) study of E7070, a novel sulphonamide, given daily X 5 every 3 weeks as a 1-hour intravenous infusion in patients (Pts) with advanced solid tumors
48. Novel agents effective against solid tumors: The diarylsulfonylureas. Synthesis, activities, and analysis of quantitative structure-activity relationships
49. Sulfonylureas: A new class of cancer chemotherapeutic agents
50. Sulfonimideamide Analogs of Oncolytic Sulfonylureas
51. Synthesis and cytotoxic evaluation of substituted sulfonyl-N-hydroxyguanidine derivatives as potential antitumor agents
52. Effects of diarylsulfonylurea antitumor agents on the function of mitochondria isolated from rat liver and GC3/CI cells
53. Cross-resistance to antitumor diarylsulfonylureas and collateral sensitivity to mitochondrial toxins in a human cell line selected for resistance to the antitumor agent N-(5-indanylsulfonyl)-N′-(4- chlorophenyl)urea
54. Antitumor diarylsulfonylureas: Novel agents with unfulfilled promise
55. Metabolism and disposition of the anticancer agent sulofenur in rat, mouse, monkey and human
56. Sulofenur cytotoxicity and changes in cytosolic calcium and mitochondrial membrane potential in human colon adenocarcinoma cell lines
57. A Circulating form of NADH oxidase activity responsive to the antitumor sulfonylurea N-(4-Methylphenylsulfonyl)-N′-(4-chlorophenyl)urea (LY181984) specific to sera from cancer patients
58. Characterization of the intracellular distribution and binding in human adenocarcinoma cells of N-(4-Azidophenylsulfonyl)-N′-(4-chlorophenyl)urea (LY219703), a photoaffinity analogue of the antitumor diarylsulfonylurea sulofenur
59. Efficacy of sulofenur and a second generation diarylsulfonylurea, N-[5-(2,3-Dihydrobenzofuryl)sulfonyl]-N-(3,4-dichlorophenyl)urea (LY295501), against colon adenocarcinoma xenografts
60. Evaluation of 5-(Indanylsulfonyl)-N-(4-chlorophenyl)urea against xenografts of pediatric rhabdomyosarcoma
61. Clinical pharmacology of a novel diarylsulfonylurea anticancer agent
62. Gouyette pharmacokinetic study of LY186641 administered daily for 2 weeks every 21 days
63. Pharmacokinetics of the anticancer agent sulofenur in mice, rats, monkeys, and dogs
64. Hammond pharmacokinetic (PK) study of the diarylsulfonylurea LY295501 administered as a single oral dose weekly for 3 weeks every 4 weeks
65. Agents that target cysteine residues of biomolecules and their therapeutic potential
66. Novel antineoplastic agents with efficacy against multidrug resistant tumor cells
67. Novel halogenated sulfonamides inhibit the growth of multidrug resistant MCF-7/ADR cancer cells
68. Selective, covalent modification of βtubulin residue Cys-239 by T138067, an antitumor agent with in vivo efficacy against multidrug-resistant tumors
69. Arylsulfonyl-N,N-diethyl-dithiocarbamates: A novel class of antitumor agents
70. Arylsulfonyl-n,n-dialkyl-dithiocarbamates as tumor cell growth inhibitors: Novel agents targeting βtubulin?
71. Matrix metalloproteinase inhibitors
72. Discovery of CGS 27023A, a non-peptidic, potent, and orally active stromelysin inhibitor that blocks cartilage degradation in rabbits
73. Design and therapeutic application of matrix metalloproteinase inhibitors
74. Protease inhibitors. Synthesis of potent matrix metalloproteinase and bacterial collagenase inhibitors incorporating N-4-Nitrobenzylsulfonyl glycine hydroxamate moieties
75. Protease inhibitors: Synthesis of a series of bacterial collagenase inhibitors of the sulfonyl amino acyl hydroxamate type
76. Inhibitors of steroidogenesis for the treatment of hormone-dependent cancers
77. Control and expression of oestrone sulphatase activities in human breast cancer
78. Development of potent non-estrogenic estrone sulfatase inhibitors
79. Sulfonylamido derivatives of aminoglutethimide and their copper(II) Complexes: A novel class of antifungal compounds
80. Steroidal and non-steroidal sulfamates as potent inhibitors of steroid sulfatase